Logo image of ZOM

ZOMEDICA CORP (ZOM) Stock Overview

USA - NYSEARCA:ZOM - CA98980M1095 - Common Stock

0.0973 USD
0 (-0.21%)
Last: 3/4/2025, 8:08:11 PM

ZOM Key Statistics, Chart & Performance

Key Statistics
Market Cap95.35M
Revenue(TTM)26.73M
Net Income(TTM)-62194000
Shares979.95M
Float961.51M
52 Week High0.2
52 Week Low0.09
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.03
PEN/A
Fwd PEN/A
Earnings (Next)05-07 2025-05-07
IPO2013-10-28
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment


ZOM short term performance overview.The bars show the price performance of ZOM in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -5 -10 -15 -20

ZOM long term performance overview.The bars show the price performance of ZOM in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of ZOM is 0.0973 USD. In the past month the price decreased by -19.59%. In the past year, price decreased by -30.94%.

ZOMEDICA CORP / ZOM Daily stock chart

ZOM Latest News, Press Relases and Analysis

ZOM Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABT ABBOTT LABORATORIES 25.49 221.35B
ISRG INTUITIVE SURGICAL INC 64.02 197.61B
BSX BOSTON SCIENTIFIC CORP 34.72 151.78B
SYK STRYKER CORP 29.86 146.70B
MDT MEDTRONIC PLC 17.02 120.74B
BDX BECTON DICKINSON AND CO 13.11 53.61B
IDXX IDEXX LABORATORIES INC 53.91 51.79B
EW EDWARDS LIFESCIENCES CORP 31.45 47.45B
RMD RESMED INC 27.14 37.83B
GEHC GE HEALTHCARE TECHNOLOGY 16.81 35.77B
PHG KONINKLIJKE PHILIPS NVR- NY 17.2 27.82B
DXCM DEXCOM INC 41.55 27.70B

About ZOM

Company Profile

ZOM logo image Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company is headquartered in Ann Arbor, Michigan and currently employs 144 full-time employees. The company went IPO on 2013-10-28. The firm is engaged in creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. The firm's product portfolio includes diagnostics and medical devices that emphasize patient health and practice health. Its Diagnostics segment consists of TRUFORMA, VetGuardian, and TRUVIEW products. Its Therapeutic Devices segment consists of Assisi and PulseVet products. Its TRUFORMA platform comprises point-of-care diagnostic products for disease states in dogs, cats and horses, providing assays for use at the point-of-care that provide reference lab accuracy. Its TRUVIEW platform consists of the TRUVIEW digital cystoscopy instrument providing microscopic images and related pathology services which enable practitioners to receive a pathologist interpretation of the images. The Assisi Loop platform includes a series of products that use targeted pulsed electromagnetic field (tPEMF) therapy.

Company Info

ZOMEDICA CORP

100 Phoenix Drive, Suite 125

Ann Arbor MICHIGAN 48108 US

CEO: Robert Cohen

Employees: 144

ZOM Company Website

ZOM Investor Relations

Phone: 17343692555

ZOMEDICA CORP / ZOM FAQ

Can you describe the business of ZOMEDICA CORP?

Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company is headquartered in Ann Arbor, Michigan and currently employs 144 full-time employees. The company went IPO on 2013-10-28. The firm is engaged in creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. The firm's product portfolio includes diagnostics and medical devices that emphasize patient health and practice health. Its Diagnostics segment consists of TRUFORMA, VetGuardian, and TRUVIEW products. Its Therapeutic Devices segment consists of Assisi and PulseVet products. Its TRUFORMA platform comprises point-of-care diagnostic products for disease states in dogs, cats and horses, providing assays for use at the point-of-care that provide reference lab accuracy. Its TRUVIEW platform consists of the TRUVIEW digital cystoscopy instrument providing microscopic images and related pathology services which enable practitioners to receive a pathologist interpretation of the images. The Assisi Loop platform includes a series of products that use targeted pulsed electromagnetic field (tPEMF) therapy.


What is the current price of ZOM stock?

The current stock price of ZOM is 0.0973 USD. The price decreased by -0.21% in the last trading session.


Does ZOMEDICA CORP pay dividends?

ZOM does not pay a dividend.


What is the ChartMill technical and fundamental rating of ZOM stock?

ZOM has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


Which stock exchange lists ZOM stock?

ZOM stock is listed on the NYSE Arca exchange.


What sector and industry does ZOMEDICA CORP belong to?

ZOMEDICA CORP (ZOM) operates in the Health Care sector and the Health Care Equipment & Supplies industry.


Can you provide the market cap for ZOMEDICA CORP?

ZOMEDICA CORP (ZOM) has a market capitalization of 95.35M USD. This makes ZOM a Micro Cap stock.


ZOM Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

ZOM Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ZOM. While ZOM has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ZOM Financial Highlights

Over the last trailing twelve months ZOM reported a non-GAAP Earnings per Share(EPS) of -0.03. The EPS decreased by -57.89% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -29.05%
ROE -30.66%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-900%
Sales Q2Q%10.29%
EPS 1Y (TTM)-57.89%
Revenue 1Y (TTM)11.33%

ZOM Forecast & Estimates

5 analysts have analysed ZOM and the average price target is 0.26 USD. This implies a price increase of 162.08% is expected in the next year compared to the current price of 0.0973.

For the next year, analysts expect an EPS growth of -110.78% and a revenue growth 10.67% for ZOM


Analysts
Analysts80
Price Target0.26 (167.21%)
EPS Next Y-110.78%
Revenue Next Year10.67%

ZOM Ownership

Ownership
Inst Owners9.39%
Ins Owners0.74%
Short Float %N/A
Short RatioN/A